During National Infertility Awareness Week, New Survey Uncovers Fertility Care Knowledge Gaps
LOS ANGELES--(BUSINESS WIRE)--In recognition of National Infertility Awareness Week, HRC Fertility, one of the largest providers of advanced fertility care, has released new data underscoring the important need for better fertility education and more inclusive care.
The March 2025 nationwide survey, commissioned by HRC Fertility in partnership with Propeller Insights, polled more than 1,000 U.S. adults ages 18–44 to understand their fertility care knowledge, treatment preferences and care expectations. The findings reflect a population eager to learn more, yet underserved when it comes to accurate information, access and culturally competent support.
Support Beyond the First Cycle
78% of survey respondents said they would be interested in a complimentary second IVF cycle if the first was unsuccessful. This highlights the emotional and financial weight families carry when undergoing fertility treatment and the importance of inclusive packages.
For many families, access to compassionate care isn't enough. Predictable pricing and peace of mind are also key. Programs like HRC Fertility's Promise Package and its popular Dream Package help reduce the emotional burden of uncertainty while reinforcing HRC Fertility's commitment to real-world support.
'With our various all-inclusive packages, and sites accessible from San Diego and Orange County, to Pasadena, Encino, Beverly Hills and the Bay Area, our goal at HRC Fertility is to educate and provide options for all walks of life when considering family building options for the future or to start their families now,' shares Kerry Ayazi, administrative President at HRC Fertility. 'These latest survey results illuminate the need for more fertility education and access and we are glad to support both.'
AMH Testing Remains Underrecognized
The survey found that 63% of adults have never heard of Anti-Müllerian Hormone (AMH) testing, a standard blood test that helps assess ovarian reserve and fertility potential. Yet 70% said they would attend a free informational session about AMH if given the opportunity.
This widespread interest reflects a gap in basic fertility education and a clear opportunity for proactive outreach. Complimentary AMH testing is being added to educational events that are increasingly offered through HRC Fertility, which stands behind its commitment to expanding access to fertility care education.
Fertility Benefits are Largely Unknown
When it comes to employer-sponsored fertility coverage, more than half of survey respondents reported not knowing what fertility benefits they currently have or whether their insurance plan covers reproductive services at all, including through plans offered by their employer.
This lack of transparency can prevent patients from accessing care when they need it most. HRC Fertility works directly with patients to navigate insurance questions, providing support from initial pre-authorization through claims submission and follow-up.
'I could not agree more on our commitment to access within reach and a transformation of family planning,' said Dr. John Wilcox, MD, Chair of HRC Fertility. 'We are ready to support patients coming to us both under existing plans as well as the new California mandated coverage plans to come; we also aim to bring this vision to Nevada soon too, with our new Las Vegas site slated to open this year, led by our own Dr. Bradford Kolb, MD.'
Methodology
HRC Fertility commissioned the nationwide Propeller Insights survey of more than 1,000 U.S. adults, aged 18 to 44, to assess their knowledge and attitudes about fertility, treatment options, benefits access and inclusive care. The survey was conducted in March 2025.
About Propeller Insights
Propeller Insights is a full-service market research firm based in Los Angeles. Using quantitative and qualitative methodologies to measure and analyze marketplace and consumer opinions, they work extensively across industries such as travel, brand intelligence, entertainment/media, retail and consumer packaged goods.
About HRC Fertility
HRC Fertility is one of the largest providers of advanced fertility treatments, boasting locations across the Bay Area as well as Los Angeles, Orange, San Bernardino, and San Diego counties, with its Las Vegas location coming soon. Welcoming individuals, couples and families from all walks of life, HRC Fertility is dedicated to helping preserve family building options for the future or start a journey towards family building now. For detailed information about HRC Fertility's services, locations and providers, please visit: www.HavingBabies.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
29 minutes ago
- Business Wire
SONU Band by SoundHealth Receives Pediatric FDA Approval
SAN FRANCISCO--(BUSINESS WIRE)-- SoundHealth, a medical technology company harnessing the power of artificial intelligence and medical science to improve patient outcomes, announced it received United States Food and Drug Administration (FDA) approval for pediatric use of its groundbreaking SONU Band. SONU is the world's first FDA De Novo authorized, AI-enabled, wearable medical device for at-home treatment of moderate to severe nasal congestion due to allergic and non-allergic rhinitis. This expanded approval makes SONU the first FDA-approved, drug-free solution for nasal congestion and allergies in children ages 12 and up, providing a safe alternative to pharmaceutical treatments. SoundHealth has developed the world's first FDA-approved, wearable device for children 12 and up that offers a drug-free, safe solution for treating nasal congestion and allergies. Share 'SONU offers a promising new option for children struggling with chronic nasal congestion. As a non-invasive, drug-free solution, it addresses a significant need among families looking for safe, effective alternatives to traditional therapies—particularly those involving steroids or medications with side effects,' said Dr. Alan Greene, Adjunct Professor of Pediatrics, Stanford University; Principal Investigator. Clinically proven to be fast-acting and effective, over 80 percent of SONU patients reported improvement in their nasal symptoms. SONU represents a brand-new category of safe and rapid relief therapies for nasal congestion and spares patients from the side effects commonly associated with other treatment options. 'Nasal congestion and allergies don't have to be life-altering,' said Dr. Paramesh Gopi, founder and CEO of SoundHealth. 'Our team of scientists, engineers and medical professionals has truly revolutionized respiratory health with AI-powered sound therapy. We are thrilled to now be able to offer relief from congestion to children and will continue to work toward helping people breathe better.' SONU is easy, convenient and pleasant to use for patients. Using SoundHealth's proprietary AI technology, the SONU app scans the patient's face using a smartphone and creates a digital map of their sinuses, calculating their optimal resonant frequencies. Following the initial one-time scan, the patient simply places the SONU Band around their head, turns it on and the band delivers frequencies tailored to the patient based on the app's calculations. The science behind SONU: SONU uses acoustic vibrational energy to provide personalized relief for nasal congestion. The band produces resonant sound waves that gently vibrate the nasal cavity. These micro vibrations help reduce swelling, open nasal passages and drain healthy mucus. Acoustic vibration associated with humming has been shown to decrease symptoms of nasal congestion, possibly through modulation of autonomic inputs to the nasal mucosa or through nitric oxide activity, which may in turn exert a decongestant and anti-inflammatory effect on the nasal passages. Using personalized, relaxing sound waves, SONU provides relief of nasal symptoms in 15 minutes or less. SONU is the only FDA-approved device equivalent to or better than the leading nasal steroid spray, calming down symptoms of allergies, inflammation and congestion. For more information, please visit About SoundHealth SoundHealth is a medical technology company that harnesses the power of artificial intelligence and medical science to improve respiratory and mental health. The SoundHealth team consists of experienced medical professionals, data scientists and engineers who are passionate about improving healthcare. Visit
Yahoo
29 minutes ago
- Yahoo
SONU Band by SoundHealth Receives Pediatric FDA Approval
SoundHealth has developed the world's first FDA-approved, wearable device for children 12 and up that offers a drug-free, safe solution for treating nasal congestion and allergies. SAN FRANCISCO, June 11, 2025--(BUSINESS WIRE)--SoundHealth, a medical technology company harnessing the power of artificial intelligence and medical science to improve patient outcomes, announced it received United States Food and Drug Administration (FDA) approval for pediatric use of its groundbreaking SONU Band. SONU is the world's first FDA De Novo authorized, AI-enabled, wearable medical device for at-home treatment of moderate to severe nasal congestion due to allergic and non-allergic rhinitis. This expanded approval makes SONU the first FDA-approved, drug-free solution for nasal congestion and allergies in children ages 12 and up, providing a safe alternative to pharmaceutical treatments. "SONU offers a promising new option for children struggling with chronic nasal congestion. As a non-invasive, drug-free solution, it addresses a significant need among families looking for safe, effective alternatives to traditional therapies—particularly those involving steroids or medications with side effects," said Dr. Alan Greene, Adjunct Professor of Pediatrics, Stanford University; Principal Investigator. Clinically proven to be fast-acting and effective, over 80 percent of SONU patients reported improvement in their nasal symptoms. SONU represents a brand-new category of safe and rapid relief therapies for nasal congestion and spares patients from the side effects commonly associated with other treatment options. "Nasal congestion and allergies don't have to be life-altering," said Dr. Paramesh Gopi, founder and CEO of SoundHealth. "Our team of scientists, engineers and medical professionals has truly revolutionized respiratory health with AI-powered sound therapy. We are thrilled to now be able to offer relief from congestion to children and will continue to work toward helping people breathe better." SONU is easy, convenient and pleasant to use for patients. Using SoundHealth's proprietary AI technology, the SONU app scans the patient's face using a smartphone and creates a digital map of their sinuses, calculating their optimal resonant frequencies. Following the initial one-time scan, the patient simply places the SONU Band around their head, turns it on and the band delivers frequencies tailored to the patient based on the app's calculations. The science behind SONU: SONU uses acoustic vibrational energy to provide personalized relief for nasal congestion. The band produces resonant sound waves that gently vibrate the nasal cavity. These micro vibrations help reduce swelling, open nasal passages and drain healthy mucus. Acoustic vibration associated with humming has been shown to decrease symptoms of nasal congestion, possibly through modulation of autonomic inputs to the nasal mucosa or through nitric oxide activity, which may in turn exert a decongestant and anti-inflammatory effect on the nasal passages. Using personalized, relaxing sound waves, SONU provides relief of nasal symptoms in 15 minutes or less. SONU is the only FDA-approved device equivalent to or better than the leading nasal steroid spray, calming down symptoms of allergies, inflammation and congestion. For more information, please visit About SoundHealth SoundHealth is a medical technology company that harnesses the power of artificial intelligence and medical science to improve respiratory and mental health. The SoundHealth team consists of experienced medical professionals, data scientists and engineers who are passionate about improving healthcare. Visit View source version on Contacts Jared@
Yahoo
2 hours ago
- Yahoo
Clinical and Pre-Clinical Data on the Novel Barriolide, EP395 (glasmacinal), Published in Three Articles in Pulmonary Pharmacology and Therapeutics
REYKJAVIK, Iceland, June 11, 2025--(BUSINESS WIRE)--EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to inhaled pathogens, has had three articles published in peer-reviewed journal, Pulmonary Pharmacology and Therapeutics. These publications describe the potential for EpiEndo's lead asset EP395, also known as 'glasmacinal', to be of therapeutic benefit in the treatment of COPD and support its continued clinical development. The article "Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial" reports that EP395 enhances the host defence response to inhaled LPS whilst reducing pro-inflammatory mediators. The paper was co-authored with investigators from Fraunhofer Institute for Toxicology and Experimental Medicine who conducted the study. The second article, "Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation" describes preclinical data that demonstrate EP395 has comparable inhibitory effects on acute neutrophilic airway inflammation to azithromycin, which is used chronically off-label for its immunomodulatory properties to reduce COPD exacerbations. Finally, "A novel macrolide, EP395, with reduced antibacterial activity and an enhancing effect on respiratory epithelial barrier" reports that EP395 has negligible antibiotic activity and enhances the barrier function of the respiratory epithelium. Maria Bech, CEO of EpiEndo Pharmaceticals commented: "It is great to see the publication of this clinical and pre-clinical research in a peer-reviewed journal, highlighting the efficacy we are seeing with glasmacinal in neutrophilic inflammation. "The anti-inflammatory effects of glasmacinal are comparable to those seen with azithromycin preclinically, but without anti-microbial activity. The clinical LPS study shows that EP395 enhances the host defence response to inhaled challenge, supporting our hypothesis that glasmacinal could be effective in reducing exacerbations in COPD but without developing anti-microbial resistance. "We continue to develop glasmacinal as a potential new oral treatment option for COPD patients, aiming to bring additional therapeutic options to patients with chronic respiratory diseases." Professor Clive Page, Emeritus Professor of Pharmacology, King's College London and Chairman of EpiEndo Pharmaceutical's Scientific Advisory Board added: "These exciting new data demonstrate glasmacinal's effect on neutrophilic inflammation both in a clinical study and in established non-clinical models of airways disease. These novel findings, coupled with data presented at ERS in 2024 on EP395's anti-inflammatory effect on eosinophilic inflammation (caused by allergens), demonstrate the broad anti-inflammatory activity of this drug that has the potential to provide a novel, groundbreaking approach to treat patients with COPD, irrespective of their type of inflammation." About EpiEndo Pharmaceuticals ( EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to chronic respiratory diseases that focuses on the role of epithelial function in various inflammatory disorders. EpiEndo's new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, known as 'Barriolides™', show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo's lead asset, glasmacinal, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD). Glasmacinal aims to be a first on-market oral treatment which is anti-inflammatory and enhances the host defense response to inhaled pathogens such as viruses, bacteria & pollution. Therefore, glasmacinal has the potential to become an impactful treatment in reducing exacerbations in patients with COPD. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030. View source version on Contacts EpiEndo Pharmaceuticals: Maria Bech, CEO+354 454 0090 Vigo Consulting (media relations):Rozi Morris+44 20 7390 0230epiendo@ Sign in to access your portfolio
